When Resectability Emerges After Systemic Therapy in Hepatocellular Carcinoma: A Proposed Response-Guided Consolidation Framework
Open Access
- 1 June 2026
- journal article
- review article
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 13, 1-8
Abstract
Immune checkpoint inhibitor–based combination therapies have increased the likelihood that a subset of patients with initially unresectable hepatocellular carcinoma (HCC) may achieve sufficient tumor regression to become technically resectable However, when resectability emerges systemic therapy, the optimal next step remains uncertain. Surgical resection may eradicate residual macroscopic disease, whereas continued systemic therapy may help maintain control of occult micrometastatic disease. In this review, we summarize the available evidence on surgical consolidation after conversion and propose a conceptual response-guided consolidation framework to support post-conversion decision-making. The current evidence base remains dominated by retrospective comparative studies, although early randomized data have recently emerged in selected populations. Overall, surgical consolidation appears feasible and may improve progression-related outcomes in carefully selected responders, but definitive survival benefit across all response categories remains unproven. Within the proposed framework, partial response appears to represent the most consistent clinical scenario supporting surgery, stable disease should be interpreted as a heterogeneous category requiring further biological and radiographic discrimination, and complete response remains the most uncertain setting in which surgery may not always be necessary. Beyond radiographic response alone, pathological response and biomarker-based predictive enrichment may help refine future selection strategies. We therefore suggest that post-conversion resectability should be viewed not simply as a technical surgical endpoint, but as a therapeutic decision point requiring multidisciplinary assessment of anatomical feasibility, response depth and durability, hepatic reserve, and biological risk. This proposed framework is intended as a practical interim model rather than an established clinical standard and requires prospective validation.Keywords
This publication has 36 references indexed in Scilit:
- 1469MO Liver resection versus continued atezolizumab plus bevacizumab (atezo/bev) in locally advanced hepatocellular carcinoma (HCC) after atezo/bev treatment (TALENTop): A multicenter, open-label, randomized phase III trialAnnals of Oncology, 2025
- BCLC strategy for prognosis prediction and treatment recommendations: The 2026 updateJournal of Hepatology, 2025
- Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004)JHEP Reports, 2025
- Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic reviewCancer Treatment Reviews, 2025
- Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 studyThe Lancet, 2023
- The impact of curative conversion therapy aimed at a cancer‐free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumabCancer Medicine, 2023
- Hepatocellular carcinomaThe Lancet, 2022
- Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitorsJournal of Hepato-Biliary-Pancreatic Sciences, 2022
- Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinomaHPB, 2019
- Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular CarcinomaGastroenterology, 2011